

Martin Kaiser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11520313/publications.pdf>

Version: 2024-02-01

65
papers

3,251
citations

126708

33
h-index

155451

55
g-index

65
all docs

65
docs citations

65
times ranked

4308
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 820768.	1.3	5
2	Intensity-adjusted therapy in autologous stem cell transplant in newly diagnosed Multiple Myeloma (FiTNess (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , 2022, 12, e056147.	0.8	11
3	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 551-555.	1.2	25
4	Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 614-627.	1.0	12
5	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021, 11, 40.	2.8	46
6	MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMJ Open</i> , 2021, 11, e046225.	0.8	18
7	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 154-161.e3.	0.2	11
8	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
9	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	2.5	56
10	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. <i>Lancet Haematology</i> , the, 2021, 8, e389-e392.	2.2	121
11	Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	0
12	OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S8.	0.2	1
13	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , 2020, 34, 604-612.	3.3	56
14	Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. <i>European Radiology</i> , 2020, 30, 320-327.	2.3	18
15	An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. <i>Blood Cancer Journal</i> , 2020, 10, 101.	2.8	11
16	Inter-observer agreement of baseline whole body MRI in multiple myeloma. <i>Cancer Imaging</i> , 2020, 20, 48.	1.2	6
17	Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. <i>Lancet Oncology</i> , The, 2020, 21, 1478-1488.	5.1	41
18	Impact of mitochondrial DNA mutations in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 46.	2.8	8

#	ARTICLE	IF	CITATIONS
19	Search for multiple myeloma risk factors using Mendelian randomization. <i>Blood Advances</i> , 2020, 4, 2172-2179.	2.5	27
20	Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. <i>British Journal of Haematology</i> , 2020, 190, e83-e86.	1.2	92
21	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	0.8	4
22	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e370-e380.	2.2	170
23	Mutational processes contributing to the development of multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 60.	2.8	41
24	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. <i>British Journal of Radiology</i> , 2019, 92, 20180822.	1.0	6
25	Regions of homozygosity as risk factors for multiple myeloma. <i>Annals of Human Genetics</i> , 2019, 83, 231-238.	0.3	2
26	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
27	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , 2019, 393, 253-264.	6.3	187
28	Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. <i>Leukemia</i> , 2018, 32, 2459-2470.	3.3	68
29	Whole-Body Imaging in Multiple Myeloma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 509-525.	0.6	15
30	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	5.8	86
31	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. <i>Leukemia</i> , 2018, 32, 1727-1738.	3.3	50
32	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
33	Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. <i>Cell Reports</i> , 2017, 20, 2556-2564.	2.9	17
34	Active multiple myeloma suppresses and typically eliminates coexisting MGUS. <i>British Journal of Cancer</i> , 2017, 117, 835-839.	2.9	2
35	Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. <i>Lancet Haematology</i> , 2017, 4, e584-e594.	2.2	6
36	Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma. <i>Haematologica</i> , 2016, 101, e142-e144.	1.7	25

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
38	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	5.8	146
39	A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial. <i>Blood</i> , 2016, 128, 3321-3321.	0.6	5
40	Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. <i>Scientific Reports</i> , 2015, 5, 12473.	1.6	16
41	Low-dose whole-body CT for staging multiple myeloma. <i>Clinical Radiology</i> , 2015, 70, S7.	0.5	2
42	Whole body diffusion weighted <sc>MRI</sc> â€“ a new view of myeloma. <i>British Journal of Haematology</i> , 2015, 171, 29-37.	1.2	80
43	The novel, orally bioavailable HSP90 inhibitor NVPâ€HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. <i>European Journal of Haematology</i> , 2012, 88, 406-415.	1.1	22
44	Synergistic action of the novel HSP90 inhibitor NVPâ€AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 337-344.	1.1	40
45	BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. <i>European Journal of Haematology</i> , 2010, 85, 99-107.	1.1	8
46	Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 134-137.	0.2	35
47	Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. <i>Experimental Cell Research</i> , 2009, 315, 2471-2478.	1.2	12
48	Serum concentrations of DKKâ€1 decrease in patients with multiple myeloma responding to antiâ€myeloma treatment. <i>European Journal of Haematology</i> , 2009, 82, 31-38.	1.1	66
49	Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IÎ²B kinase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 173-179.	1.2	44
50	Decrease in CD4+ T Cells in Multiple Myeloma Patients Receiving Bortezomib.. <i>Blood</i> , 2009, 114, 3865-3865.	0.6	1
51	Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2008, 80, 133-142.	1.1	95
52	Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). <i>Experimental Cell Research</i> , 2008, 314, 1082-1093.	1.2	44
53	Serum concentrations of DKKâ€1 correlate with the extent of bone disease in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2008, 80, 490-494.	1.1	141
54	Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of Cancer. , 2007, 176, 165-176.		21

#	ARTICLE	IF	CITATIONS
55	Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. <i>Blood</i> , 2007, 109, 2100-2105.	0.6	117
56	Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. <i>British Journal of Haematology</i> , 2007, 138, 446-458.	1.2	38
57	Bone markers in multiple myeloma. <i>European Journal of Cancer</i> , 2006, 42, 1544-1553.	1.3	50
58	Angiogenesis in multiple myeloma. <i>European Journal of Cancer</i> , 2006, 42, 1581-1590.	1.3	144
59	Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. <i>Anti-Cancer Drugs</i> , 2006, 17, 763-769.	0.7	25
60	Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. <i>European Journal of Haematology</i> , 2006, 76, 42-50.	1.1	80
61	Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. <i>European Journal of Haematology</i> , 2006, 77, 233-238.	1.1	146
62	The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. <i>Haematologica</i> , 2006, 91, 248-51.	1.7	65
63	Proteasome: an emerging target for cancer therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 475-481.	0.7	65
64	Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 200-205.	1.0	92
65	Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 687-693.	1.0	66